Monitoring and modeling treatment of atypical hemolytic uremic syndrome
- 31 May 2013
- journal article
- case report
- Published by Elsevier in Molecular Immunology
- Vol. 54 (1), 84-88
- https://doi.org/10.1016/j.molimm.2012.10.044
Abstract
No abstract availableKeywords
Funding Information
- Heart and Stroke Foundation of Canada (NA 6716)
- American Society of Nephrology (ASN) Norman Siegel Research Scholar Grant 2009
This publication has 28 references indexed in Scilit:
- Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndromePediatric Nephrology, 2010
- Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutationPediatric Nephrology, 2010
- aHUS caused by complement dysregulation: new therapies on the horizonPediatric Nephrology, 2010
- Severe atypical HUS caused by CFH S1191L—case presentation and review of treatment optionsPediatric Nephrology, 2010
- Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic SyndromeClinical Journal of the American Society of Nephrology, 2009
- Translational Mini-Review Series on Complement Factor H: Renal diseases associated with complement factor H: novel insights from humans and animalsClinical and Experimental Immunology, 2008
- Secondary failure of plasma therapy in factor H deficiencyPediatric Nephrology, 2006
- Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcomeBlood, 2006
- Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndromeThe EMBO Journal, 2006
- Atypical relapse of hemolytic uremic syndrome after transplantationPediatric Nephrology, 2004